Karolinska Development: Aprea granted Breakthrough Designation
Research Note
2020-01-31
10:50
Aprea Therapeutics reports that the company has received FDA Breakthrough Therapy Designation (BTD) for APR-246 in Combination with Azacitidine for the Treatment of Myelodysplastic Syndromes (MDS) with a TP53 Mutation.
AN
Arvid Necander
Disclosures and disclaimers